AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
ApexOnco Front Page
Recent articles
A son of glembatumumab vedotin has just started its phase 1 study.
After Astra's EsoBiotec takeover the battle for uniqueness begins.
While Sutro shows why it’s shelved luvelta-T.
YL217 will enter phase 1 before Sotio's similarly acting rival, licensed from Biocytogen.
The company buys Belgium’s EsoBiotec for $425m.
The acquisition of Araris follows a 2023 discovery collaboration.
At long last luvelta-T is shelved, and Sutro seeks a new focus.
